Compare iShares Russell 2000 ETF (IWM) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Natera Inc. Common Stock — how do they compare? iShares Russell 2000 ETF trades at $272.21 (market cap $75.59B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: iShares Russell 2000 ETF is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares Russell 2000 ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Natera Inc. Common Stock for 0 Days on average.
| IWM | NTRA | |
|---|---|---|
Market Cap | $75.59B | $57.03B |
Volume | 37,947,395 | 1,131,157 |
52-Week High | $305.06 | $425.64 |
52-Week Low | $229.13 | $179.42 |
Typical Hold Time | 83 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $276.71, down 0.42% amid bearish technical signals with 15 sell indicators versus 2 buy signals. The ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to the S&P 500 over the past decade. Recent news highlights concerns about small-cap risk premiums and competition from more selective small-cap funds.
The outlook remains challenged by interest rate sensitivity and broader market rotation away from small caps. While offering diversification from large-cap tech concentration, IWM's inclusion of unprofitable companies presents fundamental risks. Near-term performance depends on Fed policy clarity and small-cap earnings resilience.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
